Abstract
Introduction: Phosphoinositide 3-kinase (PI3K) inhibitors are a new class of cancer therapeutics that inhibits one or more enzymes in the PI3K/AKT/mTOR tumor growth pathway. As compared to other tyrosine kinase inhibitors, there is evidence that PI3K inhibitors have a higher incidence of severe cutaneous adverse events (CAEs) ranging from 2-21%. There is a lack of further characterization of clinical trials and management options for these CAEs. Methods: A retrospective chart review of our institution’s records between January 2015 and May 2019 was conducted; electronic medical records were queried by using a pharmacy database and ICD-10 codes for patients receiving PI3K inhibitor who experienced CAEs during therapy. These CAEs were characterized by two board-certified dermatologists at a major cancer center. Results: Eleven patients were identified as having 12 cumulative CAEs. Average time to rash onset was 4 weeks, and the most common identified rashes were eczematous (25%) and morbilliform (17%). Four patients experienced a dose delay, and one patient immediately discontinued their PI3K inhibitor. Conclusion: Although most CAEs caused by PI3K inhibitors in this study were limited to grade 1–2 and were controlled with topical corticosteroids and oral antihistamines, a number of patients experienced dose impact. This highlights the dermatologist’s role in managing and minimizing interruption of therapy while maintaining quality of life.
Original language | English (US) |
---|---|
Pages (from-to) | 141-146 |
Number of pages | 6 |
Journal | Journal of Immunotherapy and Precision Oncology |
Volume | 3 |
Issue number | 4 |
DOIs | |
State | Published - 2020 |
Externally published | Yes |
Keywords
- Adverse drug reaction
- Dermato-oncology
- Drug eruption
- PI3K
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Immunology
- Immunology and Allergy